Posts

Showing posts with the label Neuroepithelioma

Neuroepithelioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
 Neuroblastoma is a malignant tumor that arises from neural crest cells, which give rise to the sympathetic nervous system, and occurs mainly in children. The prognosis of neuroblastoma is affected by various genetic anomalies, such as amplification of the oncogene MYCN, numerical abnormalities of chromosomes and segmental chromosomal anomalies (including loss from 1p, from 11q, or gains of 17q). Diagnosis is based on elevated metabolites of urinary catecholamines and imaging of the initial tumor by ultrasound, brain scan, or MRI. MIBG scintigraphy and medullary analysis are useful for detecting metastases. Nephroblastoma is a differential diagnosis. Bone pain and limp can be misinterpreted as synovitis of the hip, and bilateral peri-orbital hematomas should not be mistaken for maltreatment. The prognosis of neuroblastoma is poor for approximately 60% of children over one year of age who present with metastatic disease at diagnosis, even with intensive treatment. The five-year surv...

Neuroepithelioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
Neuroblastoma is a malignant tumor that arises from neural crest cells, which give rise to the sympathetic nervous system, and occurs mainly in children. The prognosis of neuroblastoma is affected by various genetic anomalies, such as amplification of the oncogene MYCN, numerical abnormalities of chromosomes and segmental chromosomal anomalies (including loss from 1p, from 11q, or gains of 17q). Diagnosis is based on elevated metabolites of urinary catecholamines and imaging of the initial tumor by ultrasound, brain scan, or MRI. MIBG scintigraphy and medullary analysis are useful for detecting metastases. Nephroblastoma is a differential diagnosis. Bone pain and limp can be misinterpreted as synovitis of the hip, and bilateral peri-orbital hematomas should not be mistaken for maltreatment. The prognosis of neuroblastoma is poor for approximately 60% of children over one year of age who present with metastatic disease at diagnosis, even with intensive treatment. The five-year survival ...